Passage Bio board change: director resigns, new director Dolan Sondhi appointed

Passage BIO, Inc.

Thomas Woiwode resigned from Board and Compensation Committee effective July 26, 2023; no disagreement cited.
Board appointed Dr. Dolan Sondhi as Class II director effective July 27, 2023, filling a vacancy.
Dr. Sondhi is Professor of Research in Genetic Medicine at Weill Cornell, with gene therapy expertise.
Received non-incentive stock options for 48,000 shares vesting over three years under 2020 Equity Plan.
Also appointed to the Nominating and Corporate Governance Committee.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dolan Sondhi

Director

PASG · Passage BIO, Inc.

Effective: 2023-07-27
Filed: July 31, 2023, 7:59 PM ET

the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “ Governance Committee ”), appointed Dr. Dolan Sondhi as a Class II director to fill a Board vacancy

Departed

Thomas Woiwode

Director

PASG · Passage BIO, Inc.

Effective: 2023-07-26
Filed: July 31, 2023, 7:59 PM ET

Thomas Woiwode, Ph.D., notified Passage Bio, Inc. (the “ Company ”) of his decision to resign from the Company’s Board of Directors (the “ Board ”), including from the Compensation Committee of the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dolan Sondhi was appointed as Director at Passage BIO, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “ Governance Committee ”), appointed Dr. Dolan Sondhi as a Class II director to fill a Board vacancy

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Thomas Woiwode resigned as Director at Passage BIO, Inc..

Action: resigned
Role: Director

Exact text from the filing

Thomas Woiwode, Ph.D., notified Passage Bio, Inc. (the “ Company ”) of his decision to resign from the Company’s Board of Directors (the “ Board ”), including from the Compensation Committee of the Board, effective immediately.

View on SEC.gov

Passage BIO, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-085580

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.